Merck Serono collaborates with Nordic Bioscience for sprifermin in osteoarthritis

18 March 2013

German drug and chemical major Merck KGaA (MRK: DE) says its Merck Serono division has entered into a strategic alliance with Danish drug developer Nordic Bioscience Clinical Development on Merck Serono’s investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis (OA) of the knee.

Under the terms of the deal, Nordic Bioscience will provide clinical development services to Merck Serono on a shared-risk basis in exchange for a payment structure that includes service fees and potential milestone and royalty payments on the program. Further financial terms were not revealed. Merck Serono retains full responsibility for the development and commercialization of the investigational drug.

Ph IIb study to start enrolment in second-half 2013

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK